{
    "organizations": [],
    "uuid": "21232552eb8a363180f20d794c2f0fc30d816488",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-yichang-hec-changjiang-pharmaceuti/brief-yichang-hec-changjiang-pharmaceutical-co-expects-fy-profit-attributable-to-rise-at-least-70-pct-idUSFWN1PS0K9",
    "ord_in_thread": 0,
    "title": "BRIEF-Yichang Hec Changjiang Pharmaceutical Co ‍Expects FY​ Profit Attributable To Rise At Least 70 Pct",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 2 (Reuters) - Yichang Hec Changjiang Pharmaceutical Co Ltd:\n* ‍EXPECTED THAT GROUP WILL RECORD A NO LESS THAN 70 PCT INCREASE IN ITS PROFIT ATTRIBUTABLE FOR FY​\n* EXPECTED RESULT DUE TO SIGNIFICANT INCREASE IN SALES VOLUME OF COMPANY‘S KEY PRODUCT KEWEI Source text for Eikon: Further company coverage: (bangalore.newsroom@thomsonreuters.com)\n ",
    "published": "2018-02-02T16:39:00.000+02:00",
    "crawled": "2018-02-03T21:14:42.033+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "yichang",
        "hec",
        "changjiang",
        "pharmaceutical",
        "co",
        "ltd",
        "group",
        "record",
        "less",
        "pct",
        "increase",
        "profit",
        "attributable",
        "expected",
        "result",
        "due",
        "significant",
        "increase",
        "sale",
        "volume",
        "company",
        "key",
        "product",
        "kewei",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}